<p>Combination Chemotherapy of Lung Cancer – Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid–Polymer Hybrid Nanoparticles</p>

Abstract

Lung cancer is the leading cause of cancer mortality worldwide. Drug resistance is the major barrier for the treatment of non-small cell lung cancer (NSCLC). The aim of this research is to develop an aptamer-decorated hybrid nanoparticle for the co-delivery of docetaxel prodrug (DTXp) and cisplatin (DDP) and to treat lung cancer. Materials and Methods: Aptamer-conjugated lipid-polymer ligands and redox-sensitive docetaxel prodrug were synthesized. DTXp and DDP were loaded into the lipid-polymer hybrid nanoparticles (LPHNs). The targeted efficiency of aptamer-decorated, DTXp and DDP co-encapsulated LPHNs (APT-DTXp/DDP-LPHNs) was determined by performing a cell uptake assay by flow cytometry-based analysis. In vivo biodistribution and anticancer efficiency of APT-DTXp/DDP-LPHNs were evaluated on NSCLC-bearing mice xenograft. Results: APT-DTXp/DDP-LPHNs had a particle size of 213.5 ± 5.3 nm, with a zeta potential of 15.9 ± 1.9 mV. APT-DTXp/DDP-LPHNs exhibited a significantly enhanced cytotoxicity (drug concentration causing 50% inhibition was 0.71 ± 0.09 μg/mL), synergy antitumor effect (combination index was 0.62), and profound tumor inhibition ability (tumor inhibition ratio of 81.4%) compared with the non-aptamer-decorated LPHNs and single drugloaded LPHNs. Conclusion: Since the synergistic effect of the drugs was found in this system, it would have great potential to inhibit lung tumor cells and in vivo tumor growth.

Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers

“…Cell viability assays showed no significant cytotoxicity of blank NLC, which may be proof of the low toxicity of the materials used in the preparation (Wu et al., 2020 ). Chen et al reported a nanoparticle system and performed more efficient efficiency compared with free drugs on cancer cells (Chen et al., 2016 ).…”

Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy

“…Several commonly studied nanocarriers can be used to construct a co-delivery system that enables a synergistic effect between two or more medications [ 15 ]. The clinical treatment of cancer has utilized more than 20 nanotechnology-based therapeutic products [ 26 ]. With progression in the field of nanomaterials and nanotechnology, researchers have worked intensively to build multi-functional nanocarriers that can meticulously transport therapeutic agents to tumor sites [ 27 , 28 , 29 ].…”

“…Hence, there has been a surge in academic publications on co-delivery systems ascribed to the synergistic and undisruptive procedures these systems convey in treating diverse types of cancer [ 23 , 25 ]. To accomplish a guaranteed and efficient, targeted delivery of therapeutic drugs, an extensive interpretation of the interaction mechanism between the cancer cells and the DDS is essential [ 14 , 26 ]. The scope of this review was to address recent progress in the field of nanotechnology for combination therapy used in co-delivery systems.…”

Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview

“…On the other hand, the one-step method only requires a mixing of lipid and polymer, which lead both materials to selfassemble. In a recent study, a selective targeting of LPHNPs was explored by conjugating the carrier with aptamer (APT) to deliver cisplatin (CDDP) and DCX for combination therapy of NSCLC [125]. Prior to drug loading into the NPs, DCX is conjugated with glyceryl monostearate (GM) to produce a redox-sensitive DCX prodrug (DCXp).…”